A new trading day began on Tuesday, with Soleno Therapeutics Inc (NASDAQ: SLNO) stock price down -3.63% from the previous day of trading, before settling in for the closing price of $76.49. SLNO’s price has ranged from $36.93 to $76.60 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 34.73%. With a float of $39.61 million, this company’s outstanding shares have now reached $45.70 million.
In an organization with 92 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Soleno Therapeutics Inc (SLNO) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Soleno Therapeutics Inc is 20.63%, while institutional ownership is 80.58%. The most recent insider transaction that took place on Apr 01 ’25, was worth 265,156. In this transaction an insider of this company sold 3,782 shares at a rate of $70.11, taking the stock ownership to the 27,036 shares. Before that another transaction happened on Apr 01 ’25, when Company’s Officer proposed sale 3,782 for $70.11, making the entire transaction worth $265,156.
Soleno Therapeutics Inc (SLNO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.73% per share during the next fiscal year.
Soleno Therapeutics Inc (NASDAQ: SLNO) Trading Performance Indicators
Here are Soleno Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 15.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.26, a number that is poised to hit -0.97 in the next quarter and is forecasted to reach 0.37 in one year’s time.
Technical Analysis of Soleno Therapeutics Inc (SLNO)
Let’s dig in a bit further. During the last 5-days, its volume was 0.63 million. That was inferior than the volume of 1.04 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 75.60%. Additionally, its Average True Range was 3.64.
During the past 100 days, Soleno Therapeutics Inc’s (SLNO) raw stochastic average was set at 91.78%, which indicates a significant increase from 65.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.55% in the past 14 days, which was lower than the 75.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $60.33, while its 200-day Moving Average is $52.44. However, in the short run, Soleno Therapeutics Inc’s stock first resistance to watch stands at $75.76. Second resistance stands at $77.82. The third major resistance level sits at $79.58. If the price goes on to break the first support level at $71.94, it is likely to go to the next support level at $70.18. The third support level lies at $68.12 if the price breaches the second support level.
Soleno Therapeutics Inc (NASDAQ: SLNO) Key Stats
With a market capitalization of 3.68 billion, the company has a total of 49,908K Shares Outstanding. Currently, annual sales are 0 K while annual income is -175,850 K. The company’s previous quarter sales were 0 K while its latest quarter income was -55,980 K.
